President-elect Donald Trump announced his intention to appoint Marty Makary, a Johns Hopkins surgeon and author, as the next commissioner of the U.S. Food and Drug Administration (FDA). Makary, known for his skepticism about pandemic lockdowns, would work under the leadership of Robert F. Kennedy Jr. to address issues like harmful chemicals in the food supply and drugs impacting children. If confirmed by the Senate, Makary would oversee the FDAâs $7 billion budget and its regulation of $3.6 trillion in food, tobacco, and medical products, including the nationâs 20,000 prescription drugs. Makaryâs appointment aligns with Trump’s goal of tackling the “Childhood Chronic Disease Epidemic” through regulatory reform.
Makary, an accomplished transplant surgeon, gained attention during the COVID-19 pandemic for challenging mainstream recommendations on lockdowns, mask mandates, and vaccine boosters. While he supported vaccines, he argued against mandates and criticized the government’s underestimation of natural immunity. His predictions on herd immunity proved inaccurate as new variants led to a surge in virus-related deaths. Beyond the pandemic, Makary has called for reforming the FDA’s bureaucracy, which he sees as inconsistent in drug approvals, and advocated for policies to address Americaâs âpoisonedâ food supply and the overuse of pharmaceuticals, particularly in children. His views often echo those of Kennedy, who has also been tapped for a leadership role in Trumpâs health team, pending Senate approval. Together, they aim to confront what they describe as corruption and inefficiency in the nationâs health care system.
Peoplesmind
